
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc has demonstrated a robust market presence, evidenced by the significant increase in Chromium reaction volumes, which indicates continued demand for its integrated solutions despite ongoing pricing pressures. The company's consumable sales are projected to grow substantially at a rate of 5-19 times per platform by 2027, outpacing instrument revenue growth, highlighting strong potential for future profitability. As a leading provider of life science technologies, 10x Genomics is well-positioned to capitalize on its innovative product offerings amid a competitive marketplace, further strengthening its financial outlook.
Bears say
10x Genomics Inc. has experienced a contraction in 2024, marked by double-digit pricing pressure impacting revenues and a stagnation in volume growth, with expectations for recovery not anticipated until 2027. The company also reported weaker than expected results for Q4, including an earnings per share (EPS) miss and a full-year revenue outlook that fell below analyst predictions. Cumulatively, these setbacks have contributed to a significant decline in stock value, with a drop of over 90% since its peak in 2021.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares